When compared with their parental cells, cancer stem cells have an increased ability to develop resistance to EGFR-TKIs in NSCLC; EGFR-TKI-resistant sublines with stem cell-like properties are also resistant to conventional chemotherapeutic drugs, but equally sensitive to histone deacetylase and proteasome inhibitors (94, 95). The gene discussed is EGFR; the disease is cancer.